IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

Summary

This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis, administered every 2 or 4 weeks for 8 weeks

Timeline

Start

2024-07-19

Primary completion

2025-05

Completion

2025-07

Drugs

Indications